Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report

被引：13
|
作者：
Torcuator, Roy [1 ]
Zuniga, Richard [1 ]
Loutfi, Randa [2 ]
Mikkelsen, Tom [1 ,3 ]
机构：
[1] Henry Ford Hlth Syst, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA
[2] Henry Ford Hlth Syst, Hermelin Brain Tumor Ctr, Dept Med Oncol, Detroit, MI 48202 USA
[3] Henry Ford Hlth Syst, Hermelin Brain Tumor Ctr, Dept Neurol, Detroit, MI 48202 USA
来源：
JOURNAL OF NEURO-ONCOLOGY | 2009年 / 93卷 / 03期
关键词：
Brainstem; Glioma; Diffuse chemotherapy; Bevacizumab; Irinotecan; CHILDREN; CHEMOTHERAPY; RADIOTHERAPY; TRIAL;
D O I：
10.1007/s11060-008-9782-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Diffuse brainstem glioma carries a dismal prognosis. The current cornerstone of treatment is radiation therapy. Chemotherapy appears to be ineffective and the role of this treatment in the recurrent or progressive setting is not known. Bevacizumab and irinotecan have been reported to have shown radiographic response and improvement in progression-free survival among patients with malignant supratentorial gliomas. In this paper, we report our experience in an adult patient with progressive diffuse brainstem glioma treated with bevacizumab and irinotecan.
引用
收藏
页码：409 / 412
页数：4
相关论文
共 50 条
  • [31] The safety and efficacy of bevacizumab in treatment of recurrent low-grade glioma: a systematic review and meta-analysis
    Habibi, Mohammad Amin
    Rashidi, Farhang
    Gharedaghi, Hossein
    Arshadi, Mohammad Reza
    Kazemivand, Sana
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (09) : 1259 - 1270
  • [32] Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
    Tyler Y. Kang
    Tony Jin
    Heinrich Elinzano
    David Peereboom
    Journal of Neuro-Oncology, 2008, 89
  • [33] Treatment With Bevacizumab Plus Carboplatin for Recurrent Malignant Glioma
    Thompson, Eric M.
    Dosa, Edit
    Kraemer, Dale F.
    Neuwelt, Edward A.
    NEUROSURGERY, 2010, 67 (01) : 87 - 93
  • [34] Bevacizumab for the early clinical progression of diffuse intrinsic pontine glioma
    Honda, Mamoru
    Fukuoka, Kohei
    Tanami, Yutaka
    Kurihara, Jun
    Koh, Katsuyoshi
    PEDIATRICS INTERNATIONAL, 2023, 65 (01)
  • [35] Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report
    Nazarian, Javad
    Mason, Gary E.
    Ho, Cheng Ying
    Panditharatna, Eshini
    Kambhampati, Madhuri
    Vezina, L. Gilbert
    Packer, Roger J.
    Hwang, Eugene I.
    ONCOTARGET, 2016, 7 (27) : 42837 - 42842
  • [36] Brainstem Glioma in PHACES Syndrome: Case Report and Review of the Literature
    Mohebali, J.
    Walsh, M. T.
    Couldwell, W. T.
    CENTRAL EUROPEAN NEUROSURGERY, 2011, 72 (01): : 46 - 48
  • [37] Bevacizumab and Irinotecan in the Treatment of Children With Recurrent/Refractory Medulloblastoma
    Aguilera, Dolly G.
    Goldman, Steward
    Fangusaro, Jason
    PEDIATRIC BLOOD & CANCER, 2011, 56 (03) : 491 - 494
  • [38] Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis
    Artene, Stefan-Alexandru
    Turcu-Stiolica, Adina
    Hartley, Richard
    Ciurea, Marius Eugen
    Daianu, Oana
    Brindusa, Corina
    Alexandru, Oana
    Tataranu, Ligia Gabriela
    Purcaru, Stefana Oana
    Dricu, Anica
    ONCOTARGETS AND THERAPY, 2016, 9 : 6669 - 6676
  • [39] Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer
    Heinemann, Volker
    Hoff, Paulo M.
    ONCOLOGY, 2010, 79 (1-2) : 118 - 128
  • [40] Rescue bevacizumab following symptomatic pseudoprogression of a tectal glioma post-radiotherapy: a case report and review of the literature
    Timothy K. Nguyen
    James Perry
    Arun N. E. Sundaram
    Jay Detsky
    Pejman J. Maralani
    Eirena Calabrese
    Sunit Das
    Arjun Sahgal
    Journal of Neuro-Oncology, 2019, 143 : 475 - 481
12345